Homocysteine, cancer and oncothrombosis

Introduction. Hyperhomocysteinemia (HHC) is one of the arms in the pathogenesis of thrombotic complications in female cancer patients.

Aim: to assess an HHC-related impact to developing thrombotic complications in patients with malignant neoplasms of the female genital organs and breast cancer.

Materials and Methods. There were retrospectively evaluated the data collected from 236 patients: with ovarian tumors (n = 63), cervical cancer (n = 51), breast tumors (n = 64), malignant neoplasms of the uterine body (n = 58). The control group consisted of 50 women without malignant neoplasms. The analysis of homocysteine (HC) concentration, the frequency of polymorphisms of the genes encoding folate cycle enzymes MTHFR C677T, MTHFR A1298C, MTRR A66G, MTR A2756G as well as the rate of thrombotic complications was carried out. A risk of blood HC level-related thrombotic complications was assessed.

Results. Plasma HC concentration comprised ≥ 22 μmol/l in 30.5 % of patients. Thrombotic complications within one year after discharge from the hospital were developed in 15.3 % cases. The risk of thrombotic complications turned out to be higher in patients with elevated plasma HC level (≥ 22 μmol/l) (odds ratio = 2.99; 95 % confidence interval = 1.11–8.08). No significantly increased prevalence of polymorphisms in the genes encoding folate cycle enzymes among female cancer patients was detected.

Conclusion. Monitoring HC level in female cancer patients contributes separately to predict a likelihood of thrombotic complications. Prescribing drugs that reduce HC level (folic acid) and monitoring its concentration in female cancer patients during therapy, including chemotherapy, can potentially lower an incidence of thrombotic complications.

1. Alcalay A., Wun T., Khatri V. et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol. 2006;24(7):1112–8. https://doi.org/10.1200/JCO.2005.04.2150.

2. Khorana A.A., Francis C.W., Culakova E. et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–46. https://doi.org/10.1002/cncr.23062.

3. Sharma G.S., Kumar T., Dar T.A., Singh L.R. Protein N-homocysteinylation: From cellular toxicity to neurodegeneration. Biochim Biophys Acta. 2015;1850:2239–45. https://doi.org/10.1016/j.bbagen.2015.08.013.

4. Brustolin S., Giugliani R., Felix T.M. Genetics of homocysteine metabolism and associated disorders. Braz J Med Biol Res. 2010;43(1):1–7. https://doi.org/10.1590/s0100-879x2009007500021.

5. Seshadri S. Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease? J Alzheimer's Dis. 2006;9(4):393–8. https://doi.org/10.3233/jad-2006-9404.

6. Mancardi D., Penna C., Merlino A. et al. Physiological and pharmacological features of the novel gasotransmitter: hydrogen sulfide. Biochim Biophys Acta. 2009;1787(7):864–72. https://doi.org/10.1016/j.bbabio.2009.03.005.

7. Wu L.L., Wu J.T.. Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clin Chim Acta. 2002;322(1–2):21–8. https://doi.org/10.1016/s0009-8981(02)00174-2.

8. Seshadri S., Beiser A., Selhub J. et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346(7):476–83. https://doi.org/10.1056/NEJMoa011613.

9. Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999;19:217–46. https://doi.org/10.1146/annurev.nutr.19.1.217.

10. Jacques P.F., Bostom A.G., Williams R.R. et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93(1):7–9. https://doi.org/10.1161/01.cir.93.1.7.

11. Williams K.T., Schalinske K.L. New insights into the regulation of methyl group and homocysteine metabolism. J Nutr. 2007;137(2):311–4. https://doi.org/10.1093/jn/137.2.311.

12. Locasale J.W. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer. 2013;13(8):572–83. https://doi.org/10.1038/nrc3557.

13. Zhang S.M., Willett W.C., Selhub J. et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst. 2003;95(5):373–80. https://doi.org/10.1093/jnci/95.5.373.

14. Siniscalchi A., Mancuso F., Gallelli L. et al. Increase in plasma homocysteine levels induced by drug treatments in neurologic patients Pharmacol Res. 2005;52(5):367–75. https://doi.org/10.1016/j.phrs.2005.05.013.

15. Hjelt K., Brynskov J., Hippe E. et al. Oral contraceptives and the cobalamin (vitamin B12) metabolism. Acta Obstet Gynecol Scand. 1985;64(1):59–63. https://doi.org/10.3109/00016348509154689.

16. Matsuo K., Hamajima N., Hirai T. et al. Methionine synthase reductase gene A66G polymorphism is associated with risk of colorectal cancer. Asian Pac J Cancer Prev. 2002;3(4):353–9.

17. Obwegeser R., Hohlagschwandtner M., Sinzinger H. Homocysteine – a pathophysiological cornerstone in obstetrical and gynaecological disorders? Hum Reprod Update. 1999;5(1):64–72. https://doi.org/10.1093/humupd/5.1.64.

18. Montfort W.R., Perry K.M., Fauman E.B. et al. Structure, multiple site binding, and segmental accommodation in thymidylate synthase on binding dUMP and an anti-folate. Biochemistry. 1990;29(30):6964–77. https://doi.org/10.1021/bi00482a004.

19. Blount B.C., Mack M.M., Wehr C.M. et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci U S A. 1997;94(7):3290–5. https://doi.org/10.1073/pnas.94.7.3290.

20. Hay R.K., Park J.-G., Gazdar A. Atlas of human tumor cell lines. Academic Press, 2013. 490

21. Crider K.S., Yang T.P., Berry R.J., Bailey L.B. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role. Adv Nutr. 2012;3(1):21–38. https://doi.org/10.3945/an.111.000992.

22. Hall L.E., Mitchell S.E, O’Neill R.J. Pericentric and centromeric transcription: a perfect balance required. Chromosome Res. 2012;20(5):535–46. https://doi.org/10.1007/s10577-012-9297-9.

23. Ehrlich M. DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements. J Nutr. 2002;132(8 Suppl):2424S–2429S. https://doi.org/10.1093/jn/132.8.2424S.

24. Zhang D., Wen X., Wu W. et al. Elevated homocysteine level and folate deficiency associated with increased overall risk of carcinogenesis: metaanalysis of 83 case-control studies involving 35,758 individuals. PLoS One. 2015;10(5):e0123423. https://doi.org/10.1371/journal.pone.0123423.

25. Stathopoulou A., Vlachonikolis I., Mavroudis D. et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. J Clin Oncol. 2002;20(16):3404–12. https://doi.org/10.1200/JCO.2002.08.135.

26. Mcdonald L., Bray C., Field C. et al. Homocystinuria, thrombosis, and the blood-platelets. Lancet. 1964;1(7336):745–6. https://doi.org/10.1016/s0140-6736(64)92852-1.

27. Tonetti C., Amiel J., Munnich A., Zittoun J. Impact of new mutations in the methylenetetrahydrofolate reductase gene assessed on biochemical phenotypes: a familial study. J Inherit Metab Dis. 2001;24(8):833–42. https://doi.org/10.1023/a:1013988123902.

28. Sibani S., Christensen B., O'Ferrall E. et al. Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria. Hum Mutat. 2000;15(3):280–7. https://doi.org/10.1002/(SICI)1098-1004(200003)15:3<280::AID-HUMU9>3.0.CO;2-I.

29. Kluijtmans L.A., Wendel U., Stevens E. et al. Identification of four novel mutations in severe methylenetetrahydrofolate reductase deficiency. Eur J Hum Genet. 1998;6(3):257–65. https://doi.org/10.1038/sj.ejhg.5200182.

30. Brezovska-Kavrakova J., Krstevska M., Bosilkova G. et al. Hyperhomocysteinemia and of methylenetetrahydrofolate reductase (C677T) genetic polymorphism in patients with deep vein thrombosis. Mater Sociomed. 2013;25(3):170–4. https://doi.org/10.5455/msm.2013.25.170-174.

31. van der Put N.M., Steegers-Theunissen R.P., Frosst P. et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 1995;346(8982):1070–1. https://doi.org/10.1016/s0140-6736(95)91743-8.

32. Robien K., Ulrich C.M. 5, 10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol. 2003;157(7):571–82. https://doi.org/10.1093/aje/kwg024.

33. Weisberg I.S., Jacques P.F., Selhub J. et al. The 1298A→ C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis. 2001;156(2):409–15. https://doi.org/10.1016/s0021-9150(00)00671-7.

34. Alberg A.J., Selhub J., Shah K.V. et al. The risk of cervical cancer in relation to serum concentrations of folate, vitamin B12, and homocysteine. Cancer Epidemiol Biomarkers Prev. 2000;9(7):761–4.

35. Powers H.J. Interaction among folate, riboflavin, genotype, and cancer, with reference to colorectal and cervical cancer. J Nutr. 2005;135(12 Suupl):2960S–2966S. https://doi.org/10.1093/jn/135.12.2960S.

36. Gatt A., Makris A., Cladd H. et al. Hyperhomocysteinemia in women with advanced breast cancer. Int J Lab Hematol. 2007;29(6):421–5. https://doi.org/10.1111/j.1751-553X.2007.00907.x.

37. Heit J.A., O'Fallon W.M., Petterson T.M. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a populationbased study. Arch Intern Med. 2002;162(11):1245–8. https://doi.org/10.1001/archinte.162.11.1245.

38. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338(15):1042–50. https://doi.org/10.1056/NEJM199804093381507.

39. Sharma G.S., Kumar T., Singh L.R. N-homocysteinylation induces different structural and functional consequences on acidic and basic proteins. PLoS One. 2014;9:e116386. https://doi.org/10.1371/journal.pone.0116386.

40. Kumar T., Sharma G.S., Singh L.R. Homocystinuria: therapeutic approach. Clin Chim Acta. 2016;458:55–62. https://doi.org/10.1016/j.cca.2016.04.002.

41. Lentz S.R., Sobey C.G., Piegors D.J. et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst (e) inemia. J Clin Invest. 1996;98(1):24–9. https://doi.org/10.1172/JCI118771.

42. FitzGerald G.A. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet. 2003;361(9357):542–4. https://doi.org/10.1016/S0140-6736(03)12560-3.

43. Sibrian-Vazquez M., Escobedo J.O., Lim S. et al. Homocystamides promote free-radical and oxidative damage to proteins. Proc Natl Acad Sci U S A. 2010;107(2):551–4. https://doi.org/10.1073/pnas.0909737107.

44. Zhang J.-.W, Yan R., Tang Y.-S. et al. Hyperhomocysteinemia-induced autophagy and apoptosis with downregulation of hairy enhancer of split 1/5 in cortical neurons in mice. Int J Immunopathol Pharmacol. 2017;30(4):371–82. https://doi.org/10.1177/0394632017740061.

45. Škovierová H., Vidomanová E., Mahmood S. et al. The molecular and cellular effect of homocysteine metabolism imbalance on human health. Int J Mol Sci. 2016;17(10):1733. https://doi.org/10.3390/ijms17101733.

46. Biron F., Rousseau J., Baulin J. et al. Thromboembolic event and metabolic hyperhomocysteinemia: A case report and review of literature. Ann Cardiol Angeiol (Paris). 2021;70(3):177–82. (In French). https://doi.org/10.1016/j.ancard.2021.01.008.

47. Aday A.W., Duran E.K, Van Denburgh M. et al. Homocysteine is associated with future venous thromboembolism in 2 prospective cohorts of women. Arterioscler Thromb Vasc Biol. 2021;41(7):2215–24. https://doi.org/10.1161/ATVBAHA.121.316397.